Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries - Report - MDSpire
Advertisement
Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries
Clinical Report: Efficacy and Safety of Blinatumomab in Adult B-ALL
Overview
This study evaluates the efficacy and safety of blinatumomab in adult patients with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) across 13 European countries. The findings indicate high response rates in both measurable residual disease-positive and relapsed/refractory patients, with significant implications for treatment strategies.
Background
Blinatumomab is a bispecific T-cell engager that has been approved for treating measurable residual disease-positive and relapsed/refractory BCP-ALL. Understanding its real-world effectiveness and safety is crucial for optimizing treatment protocols in this challenging patient population. This study provides insights into the outcomes of a diverse cohort of adult patients treated with blinatumomab.
Data Highlights
Group
Patients
MRD Response Rate
Overall Survival (24-month)
MRD+
46
81.8%
67%
R/R
183
75.4%
52%
Key Findings
81.8% of evaluable MRD+ patients achieved an MRD response.
In the R/R group, 82.0% achieved complete remission or similar outcomes.
Median disease-free survival for MRD+ patients was 31.2 months.
24-month overall survival was 67% for MRD+ and 52% for R/R patients.
Patients with late first relapse had better outcomes than the overall R/R group.
Clinical Implications
The high response rates and overall survival outcomes suggest that blinatumomab is an effective treatment option for adult patients with BCP-ALL, particularly in those with MRD+ disease. Clinicians should consider early administration of blinatumomab to maximize patient outcomes and evaluate the potential benefits of proceeding to allo-HSCT post-treatment.
Conclusion
Blinatumomab demonstrates significant efficacy and safety in adult patients with BCP-ALL, supporting its use as a key therapeutic option in this population. Further studies are warranted to refine treatment strategies and optimize patient management.
